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LeukemiaThe phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway
mediates diverse and important physiological cell functions which include proliferation, differentiation, survival,
motility, autophagy, andmetabolism.However, dysregulated PI3K/Akt/mTOR signaling has beendocumented in
a wide range of neoplasias, including malignant hematological disorders. It is now emerging that this signaling
networkplays a key roleduring normalhematopoiesis, a tightly regulatedprocess resulting in the formation of all
blood lineages. Blood cell development encompasses a complex series of events which are mainly regulated by
actions of cytokines, a family of extracellular ligandswhich stimulatemanybiological responses in awide array of
cell types. Hematopoiesis is strictly dependent on the correct function of the bone marrow microenvironment
(BMM), as BMM cells secrete most of the cytokines. Several of these cytokines activate the PI3K/Akt/mTOR
signaling network and regulate proliferation, survival, and differentiation events during hematopoiesis. Here, we
review the evidence that links the signals emanating from the PI3K/Akt/mTOR cascade with the functions of
hematopoietic stem cells and the process ofmyelopoiesis, including lineage commitment. We then highlight the
emerging role played by aberrant PI3K/Akt/mTOR signaling during leukemogenesis.tomiche Umane, Università di
fax: +39 051 2091695.
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The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target
of rapamycin (mTOR) signaling cascade is crucial to widely divergent
physiological processes, which include cell cycle progression,
differentiation, transcription, translation, apoptosis, endocytosis,
motility, autophagy, and metabolism [1]. Moreover, a clear link
between this pathway and cancer has been established already in the
1980s, and in recent years it has become apparent that this signal
transduction network is one of the most frequently aberrantly
regulated pathways in human tumors [1]. Since therapeutic targeting
of the PI3K/Akt/mTOR axis is being considered as an option for
innovative treatment of several types of cancers, including hemato-
poietic malignancies [2,3], it becomes of critical importance to
establish the role, if any, of this network in normal myelopoiesis.
Indeed, myelosuppression is often a dose-limiting effect of tradi-
tional cytotoxic drugs. Therefore, the aim of this review is to highlight
the relevance of PI3K/Akt/mTOR signaling during normal myelopoi-esis in the adult. Moreover, we will also discuss the emerging
evidence that links pathway activation with leukemogenesis.
However, we shall begin with a general overview outlining the
mechanismswhich regulate the PI3K/Akt/mTOR signal transduction
network.
2. The PI3K/Akt/mTOR pathway
2.1. PI3K
PI3Ks belong to a conserved family of intracellular lipid kinases that
catalyze the phosphorylation of the D3 position of inositol lipids. PI3K
products then act as second messengers and mediate reversible
membrane localization of cytoplasmic proteins. There are three
different PI3K classes: I, II, and III. Class I PI3K phosphorylates both
phosphatidylinositol (PtdIns) 4 phosphate and PtdIns 4,5 bispho-
sphate [PtdIns (4,5)P2] to yield PtdIns (3,4)P2 and PtdIns 3,4,5
trisphosphate [PtdIns (3,4,5)P3], respectively. However, the in vivo
preferred substrate of class I PI3K is PtdIns (4,5)P2 [4]. PtdIns (3,4)P2
and PtdIns (3,4,5)P3 recruit to the plasma membrane pleckstrin
homology (PH) domain-containing proteins, including Akt and
phosphoinositide-dependent protein kinase 1 (PDK1). Class I PI3K is
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comprising a regulatory (p85α, p85β, p55α, p55γ, and p50α) and a
catalytic (p110α, p110β, and p110δ) subunits. They act downstreamof
both tyrosine kinase receptors (TKRs) and G protein-coupled
receptors (GPCRs) (Fig. 1). The single class IB PI3K comprises a p101
regulatory and a p110γ catalytic subunits and is activated downstream
of GPCRs [5]. p110α and p110β PI3Ks are ubiquitously expressed in
mammalian tissues/organs and play key roles during development
and cell growth. Therefore, their homozygous knockout is embryonic-
lethal [6]. In contrast, p110γ and p110δ PI3Ks are highly enriched in
leukocytes, so that their knockdowns lead to impaired immune
responses [7].
Class II PI3Ks, which comprise the PI3K-C2α, -C2β, and -C2γ
isoforms, preferentially phosphorylate PtdIns to yield PtdIns (3)P.
They are downstream of TKRs and GPCRs, although their mechanism
of activation most likely differs from that of Class I isoenzymes [8].
Class II PI3Ks are widely expressed in mammalian tissues/organs,
however, their importance in cell signaling and biology, relative to
that of class I PI3Ks, is not clear at the moment [9]. They could be
involved in cell motility and exocytosis [8]. Vacuolar protein sorting
34 (vps34), is the only class III PI3K and exists as a heterodimer bound
to the vps15 regulatory subunit (formerly called p150 in mammals).
Vps34 has been implicated in autophagy, endocytosis, protein
synthesis, and nutrient signaling [10,11].Fig. 1. The PI3K/Akt/mTOR pathway. GPCRs, RTKs, and Ras stimulate class I PI3K activity. PI3
membrane PDK1 that phosphorylates Akt on Thr308. Full Akt activation requires Ser473
including GSK3β, FOXO transcription factors, CREB, SKP2, MDM2, and Bad. Active Akt in
association with TSC1 to inactivate the small G protein Rheb. Akt-driven TSC1/TSC2 com
upregulates, through amechanism not yet fully elucidated, the protein kinase activity of mTO
p90RSK pathway, the AMPK network, REDD1, and Wnt/GSK3β. mTORC1 targets p70S6K an
mTORC2 regulates actin polymerization and phosphorylates PKCα and SGK1. The regula
perpendicular lines highlight inhibitory events.2.2. Akt
Akt is a 57-kDa enzyme, belonging to the AGC protein kinase
family. Akt, also referred to as protein kinase B (PKB), is the cellular
homolog of the v-akt oncogene. The Akt family includes three highly
conserved isoforms: Akt1/α, Akt2/β, and Akt3/γ. Whereas Akt1 and
Akt2 are ubiquitously expressed, Akt3 displays a more restricted
tissue distribution and is found abundantly in nervous tissue [4]. All
Akt isoforms share structural homology, including PH domain, ATP
binding site, and two phosphorylation sites. Genetic studies have
disclosed that Akt isoforms exert non-redundant functions, despite
their high sequence similarity. While Akt1 null mice have overall
growth retardation, Akt2 null mice develop insulin-resistance and
diabetes. In contrast, Akt3 null mice display reduced brain size [12].
Akt recruitment at the plasma membrane by PtdIns (3,4)P2 and
PtdIns (3,4,5)P3 results in a conformational change [4], that enables
the activation segment of Akt to be phosphorylated on Thr308 by
PDK1, while Ser473 in the hydrophobic motif is targeted by a kinase
that has been identiﬁed as the mTOR complex 2 (mTORC2) (Fig. 1),
although other kinases could also be involved. These kinases include
integrin-linked kinase, and DNA-dependent kinase [13]. Full Akt
activation requires both the phosphorylation steps. Active Akt
migrates to the cytosol, the mitochondria, and the nucleus. Nuclear
Akt fulﬁls important anti-apoptotic roles [14]. However, the relativeK generates PtdIns (3,4,5)P3 from PtdIns (4,5,)P2. PtdIns (3,4,5)P3 attracts to the plasma
phosphorylation by mTORC2. Once activated, Akt phosphorylates several substrates,
hibits TSC2 activity through direct phosphorylation. TSC2 is a GAP that functions in
plex inactivation allows Rheb to accumulate in a GTP-bound state. Rheb-GTP then
RC1. However, other signals impinge onmTORC1, including the Ras/Raf/MEK/ERK1/2/
d 4E-BP1 which are critical for translation. Ribosomal S6 protein is a target of p70S6K.
tion of mTORC2 activity is still unclear. Arrows indicate activating events, whereas
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established.
At present, over 100 Akt substrates have been identiﬁed [15].
Around 40 substrates which mediate the pleiotropic Akt functions
have been characterized, including caspase-9, Bad, murine double
minute 2 (MDM2, a negative regulator of p53), proline-rich Akt
substrate 40 (PRAS40), FOXO family of Forkhead transcription factors,
apoptosis signal-regulated kinase 1 [ASK1, a negative regulator of pro-
apoptotic c-Jun N-terminal kinase (JNK)], Raf, S-phase kinase-
associated protein 2 (SKP2), p27Kip1, p21Cip1, glycogen synthase kinase
3β (GSK3β), and cAMP response element-binding protein (CREB).
Each of these substrates plays a key role in the regulation of cell
proliferation, differentiation, and survival, either directly or through
an intermediary [5,16,17].
2.3. mTOR
mTOR is an atypical 289-kDa serine/threonine kinase, originally
identiﬁed in the yeast Saccharomyces cerevisiae, that belongs to the
PI3K-related kinase family and displays a COOH-terminal catalytic
domain with a high sequence homology to PI3K. In spite of this
homology, mTOR functions exclusively as a protein kinase [18]. mTOR
signaling is conserved in eukaryotes from plants and yeasts to
mammals. mTOR exists as two multi-protein complexes, referred to as
mTOR complex 1 (mTORC1) and mTORC2 (Fig. 1). mTORC1 is
comprised of mTOR/Raptor/mLST8/PRAS40/FKBP38/Deptor and is
sensitive to rapamycin and its derivatives (rapalogs). mTORC2 is
composed of mTOR/Rictor/mLST8/SIN1/Protor/Deptor and is gener-
ally described as being insensitive to rapamycin/rapalogs, although
long-term treatment of about 20% of cancer cell lines with rapamycin/
rapalogs leads to dissociation of mTORC2 [19,20]. Recently, a short (80-
kDa) mTOR splicing variant, referred to as mTORβ, has been identiﬁed.
mTORβ interacts with both Raptor and Rictor. It has been proposed that
mTORβ, but not the full-length mTORα, is responsible for coordinating
cell cycle progression and cell proliferation. Moreover, mTORβ was
tumorigenic in nudemiceand couldbeaprotooncogene [21]. Deptor is a
recently-identiﬁed, intriguing component of both mTORC1 and
mTORC2 [22]. Loss of Deptor activated p70S6 kinase (p70S6K), Akt,
and serum- and glucocorticoid-induced protein kinase 1 (SGK1, that
belongs to the AGC kinase family), promoted cell growth and survival,
and upregulated both mTORC1 and mTORC2 kinase activities. Deptor
overexpression suppressedp70S6Kbut, by relieving feedback inhibition
frommTORC1 to PI3K signaling (see later on), activated Akt. Consistent
with many human cancers having activated mTORC1 and mTORC2
pathways, Deptor expression is low in most neoplasias [22]. Surpris-
ingly, Deptor was found highly overexpressed in a subset of multiple
myelomas harboring chromosomal translocations. However, in these
cells, high Deptor expression was required to maintain PI3K/Akt
activation and a reduction in Deptor levels led to apoptosis.
mTORC1 signaling integrates environmental clues (oxygen levels,
growth factors, hormones, nutrients, and stressors) and information
from the cell metabolic status. Thus, mTORC1 controls anabolic
processes for promoting protein synthesis and cell growth [23].
mTORC1 regulates translation in response to nutrients/growth factors
by phosphorylating components of the protein synthesis machinery,
including p70S6K and 4E-BP1 (eukaryotic initiation factor 4E-binding
protein 1). p70S6K phosphorylates the 40S ribosomal protein, S6,
leading to active translation of mRNAs, while 4E-BP1 phosphorylation
by mTORC1 on several amino acidic residues (Thr37; Thr46; Ser65;
Thr70) results in the release of the eukaryotic initiation factor 4E
(eIF4E). eIF4E is a key component for translation of 5′ capped mRNAs,
which include transcripts encoding growth and survival promoting
molecules, such as c-Myc, cyclin D1, cyclin-dependent kinase 2,
retinoblastoma protein, p27Kip1, vascular endothelial growth factor
(VEGF), and signal activator and transducer of transcription 3 (STAT3)
[19,24].Besides protein synthesis, it is now beginning to emerge that
mTORC1 could control lipid synthesis as well as mitochondrial
metabolism and biogenesis [25]. Furthermore, mTORC1 negatively
regulates autophagy, a catabolic processwhich is important in organelle
degradation and protein turnover [26,27].
Akt-mediated regulation of mTORC1 activity involves several
mechanisms. Akt phosphorylates Tuberous Sclerosis 2 (TSC2 or
hamartin) at multiple sites, which include Ser 939, Ser 981, and Thr
1462. TSC2 is a GTPase-activating protein (GAP) that associates with
Tuberous Sclerosis 1 (TSC1 or tuberin) for inactivating the small G
protein Ras homolog enriched in brain (Rheb). When phosphorylated
by Akt, TSC2 binds 14-3-3 protein [28]. This then reduces the GAP
activity of the TSC1/TSC2 complex, allowing Rheb to accumulate in a
GTP-bound state. The mechanism by which Rheb-GTP activates
mTORC1 has not been fully elucidated yet, although Rheb requires to
be farnesylated for activating mTORC1 [29]. Akt also phosphorylates
PRAS40, an inhibitor of the interactions between mTORC1 and its
substrates, and by doing so, prevents PRAS40 ability to suppress
mTORC1 signaling [30]. Moreover, PRAS40 is a substrate of mTORC1
itself, and it has been demonstrated that mTORC1-mediated phosphor-
ylation of PRAS40 facilitates the removal of its inhibition on mTORC1
[31]. Furthermore, Ras/Raf/mitogen-activated protein kinase kinase
(MEK)/extracellular signal-regulated kinase (ERK) 1/2 signaling pos-
itively regulatesmTORC1 activity, as bothERK1/2 andp90 ribosomal S6
kinase (p90RSK) phosphorylate TSC2, thus suppressing its inhibitory
function on Rheb [32]. Another signaling pathway which impinges on
mTORC1 is theWnt/GSK3β cascade [33], as it has beendocumented that
Wnt stimulation could activate mTORC1 by inhibiting the TSC2
phosphorylation driven by GSK3β [34] (Fig. 1). mTORC1 signal
transduction is inhibited by the master metabolic regulator, energy-
sensing AMP-dependent protein kinase (AMPK), as AMPK phosphor-
ylates TSC2 on Ser 1345. This phosphorylative event primes TSC2 for
subsequent phosphorylation by GSK3β on Ser 1337 and Ser 1341 [35].
Indeed, the coordinatedphosphorylation of TSC2byAMPKandGSK3β is
required for maximal activation of TSC2 and inhibition of mTORC1
[18,34]. However, AMPK also phosphorylates Raptor and this phos-
phorylation induces 14-3-3 protein binding to Raptor. The phosphor-
ylation of Raptor byAMPK is necessary for the inhibition ofmTORC1and
cell cycle arrest induced by energy stress [36].
For the purposes of this review, it is also important to emphasize
here that hypoxia inhibits mTORC1 activity through induction of
REDD1 (Regulated in Development and DNA damage responses) and
REDD1-mediated dissociation of growth factor-stimulated TSC2/14-
3-3-complex formation [37].
The mechanisms for TORC2 regulation have only begun to be
revealed. However, mTORC2 activation requires PI3K and the TSC1/
TSC2 complex, but is independent of Rheb and is largely insensitive to
either nutrients or energy conditions [38]. mTORC2 phosphorylates Akt
on Ser473 that enhances subsequent Akt phosphorylation on Thr308 by
PDK1 [39]. Moreover, mTORC2 plays a role in cytoskeleton organization
by controlling actin polymerization [40] and phosphorylates protein
kinase C (PKC) α [38]. The oncogenetic role of mTORC2 has been
recently highlighted by an investigation that documented the impor-
tance of mTORC2 in the development and progression of prostate
cancers induced in mice by PTEN (phosphatase and tensin homolog
deleted on chromosome 10) loss [41]. Another downstream target of
mTORC2 is SGK1 [42]. There is now evidence that mTORC2 could
facilitate cell proliferation through SGK1 and not Akt, at least in some
experimental models [17].
Akt andmTORC1/2 are linked to each other via positive andnegative
regulatory feedback circuits, which restrain their simultaneous hyper-
activation through mechanisms involving p70S6K and PI3K. Once
mTORC1 is activated through Akt, the former elicits a negative feedback
loop for inhibiting Akt activity [19]. This negative regulation of Akt
activity by mTORC1 is a consequence of p70S6K-mediated phosphor-
ylation of insulin receptor substrate (IRS) 1 adapter protein,
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receptor [43–45]. Indeed, IRS1 phosphorylation on Ser307 and Ser636/
639 by p70S6K targets the adapter protein to proteasomal degradation
[46]. Therefore, at least in principle, inhibition of mTORC1 activity by
rapamycin/rapalogs could result in hyperactivation of both Akt and its
downstream targets. Such a phenomenon has been documented to
occur both in vitro and in vivo [47,48]. mTORC1 is capable of
downregulating also IRS2 expression by enhancing its proteosomal
degradation [49]. Recent work has also highlighted a p70S6K-mediated
phosphorylation of Rictor on Thr 1135. This phosphorylative event
exerted a negative regulatory effect on the mTORC2-dependent
phosphorylation of Akt in vivo [50]. Thus, both mTORC1 and mTORC2
control Akt activation.
3. Negative regulation of PI3K/Akt/mTOR signaling
Phosphorylated inositol lipids are not hydrolyzed by any known
phospholipase. Therefore, the activity of several phosphatases is
instrumental to counterbalance PI3K/Akt/mTOR signaling activation.
PTEN is a dual speciﬁcity lipid and protein phosphatase that preferen-
tially removes the 3′-phosphatemainly fromPtdIns (3,4,5)P3, but is also
active on PtdIns (3,4,)P2, thereby antagonizing network signaling
[51,52]. PTEN inactivatingmutations or silencing occur in awide variety
of human cancers and this results in Akt/mTORupregulation. Two other
phosphatases, SHIP1 and SHIP2 (for Src homology domain-containing
inositol phosphatase), remove the 5-phosphate from PtdIns (3,4,5)P3 to
yield PtdIns (3,4,)P2 [53]. While SHIP1 is predominantly expressed in
hematopoietic cells, SHIP2 is more ubiquitous. Protein phosphatase 2A
(PP2A) downregulates Akt activity directly, by dephosphorylating
Thr308 [54]. Additionally, Thr308 and Ser473 residues of Akt are
targeted by the two isoforms (1 and 2) of PHdomain leucine-rich repeat
protein phosphatase (PHLPP) [55].
4. Normal hematopoiesis
Sincemost blood cells display a very short life, every day billions of
mature blood cells are replenished in humans, during steady-state
hematopoiesis. Moreover, the hematopoietic system also needs to
quickly respond when physiological demands (e.g. bleeding and
infection) dictate [56]. The integrity of hematopoiesis is strictly
dependent on the existence and persistence in the adult bonemarrow
of the rare hematopoietic stem cells (HSCs) which display both an
extensive self-renewal capacity and the ability to sustain all blood cell
lineages throughout lifetime [57]. HSCs are deﬁned operationally by
their capacity to reconstitute the entire blood system of a recipient
[58,59]. At least two types of HSC have been identiﬁed, long-term
HSCs (LT-HSCs) and short-term HSCs (ST-HSCs) [60,61]. LT-HSCs can
provide long-term (N4 months) hematopoietic reconstitution in the
recipient and possess a high self-replicating activity (Fig. 2).
The prevailingmodel for adult hematopoietic lineage commitment
is considered as a pyramidal/hierarchical model, implying that the
ﬁrst lineage commitment step of HSCs results in a strict separation of
lymphopoiesis and myelopoiesis, giving origin to common lymphoid
(CLP) and myeloid (CMP) progenitors. These progenitors are capable
of exponential proliferation, as well as continuing the differentiation
process [58,62]. While CLP will ultimately develop into natural killer
(NK), T, and B lymphocytes, CMP will evolve into megakaryocyte/
erythroid (MEP) and granulocyte/monocyte (GMP) committed
progenitors [63,64], which then give rise to myeloid lineage
committed cells [65] (Fig. 2). Therefore, myeloid cells comprise
erythrocytes, megakaryocytes, and granulocytes/monocytes. An al-
ternative commitment route entails the existence of progenitors
which are restricted to lymphocytes and granulocytes/monocytes, but
displaying little or no megakaryocyte/erythroid potential [66].
It is widely assumed that the dividing HSCs in bone marrow
undergo asymmetric cell division, in which a HSC gives rise to twonon-identical daughter cells, one keeping the HSC identity tomaintain
their number constant and the other becoming a more differentiated
progenitor cell. HSC activity needs to be tightly regulated so as tomeet
physiological demands, but also to protect HSCs from physical,
chemical, and oncogenetic damage [67]. The site or physical
microenvironment that regulates self-renewal, proliferation, and
differentiation of HSCs is referred to as the “HSC niche” [68,69].
Currently, two types of HSC niches have been identiﬁed in bone
marrow, the endosteal niche located on the surface of trabecular bone,
and the vascular niche at the bone marrow sinusoids, which are low-
pressure blood vessels with a fenestrated endothelium located in the
center of the bonemarrow [70].While the vascular niche is permissive
for proliferation anddifferentiation, the endosteal niche facilitates HSC
maintenance and quiescence [71]. The vascular niche constitutes a
barrier somehowsimilar to the basementmembrane for regulating the
release of only the most mature hematopoietic elements, such as
erythrocytes, mature granulocytes/monocytes, and platelets [72].
The niches are composed of different cells, which include
osteoblasts, osteoclasts, endothelial cells, ﬁbroblasts, and adipocytes
[73]. These cells, which are part of the bone marrow microenviron-
ment (BMM), produce the factors which are necessary for supporting
HSC functions.
Basal and emergency hematopoiesis is mostly regulated by
cytokines, a large family of extracellular ligands which can stimulate
a wide array of biological responses in many cell types [74]. Several
studies have strongly suggested that osteoblasts residing on the bone
surface are key components of the endosteal HSC niche, as osteoblast
cell lines secrete many cytokines which promote the proliferation of
hematopoietic cells in culture, and support the in vitromaintenance of
HSCs [70]. Cytokines can be arranged in a hierarchical system with
broadly acting cytokines such as stem cell factor (SCF, the ligand for
c-Kit tyrosine kinase receptor) and interleukin (IL) -2, -3, or -7 acting
on multipotential cells, and lineage-speciﬁc cytokines, such as
erythropoietin (EPO), acting on speciﬁc lineages [56] (Fig. 2).5. PI3K/Akt/mTOR signaling and normal myelopoiesis
5.1. HSC maintenance
Most adult HSCs are in a quiescent state, i.e. they are in theG0 phase
of the cell cycle, while only a small (5%) subset is dividing [75]. Inmice,
it has been estimated that HSCs experience a single cell division every
2–4 weeks [76]. It has been hypothesized that quiescence is one of the
major mechanisms to keep HSC function and protect them from
environmental clues [77]. Our knowledge of the soluble factors which
could be involved inHSC quiescence is limited. Recentﬁndings suggest
that HSCs could be maintained in a quiescent state through interac-
tions with thrombopoietin (TPO)-producing osteoblasts [78]. Never-
theless, other investigators have documented that TPO works in
synergy with IL-3 and SCF to promote proliferation in vitro of both
murine andhumanHSCs [79,80]. It is therefore plausible that a delicate
balance in positive and negative signals downstream from the TPO
receptor plays a role in the regulation of the probability of self-renewal
of HSCs [81].
Studies from independent laboratories have demonstrated that if
HSCs undergo uncontrolled proliferation, they lose their long-term
functions. It is now emerging that PI3K/Akt/mTORC1 signaling plays
important roles in HSC maintenance. Indeed, it has been reported that
lipid-raft clustering induced by SCF and TPO could be critically
involved in mouse LT-HSC re-entry into the cell cycle by upregulation
of Akt that thereby decreased FOXO3a transcription factor activity
[82]. Also, acute treatment with interferon α (INFα) increased Akt1
phosphorylation in mice HSCs and this correlated with their entering
an active cell cycle. However, chronic INFα exposure, impaired HSC
function in repopulation assays [83].
Fig. 2. Schematic of the current model for adult hematopoiesis highlighting intermediates in the hematopoietic differentiation hierarchy. Hematopoiesis progresses from LT-HSCs
(which are capable of self-renewal) to ST-HSCs which differentiate into multilineage committed CMP and CLP. ST-HSCs then give rise to more differentiated dual progenitors,
including those committed to myelopoiesis, i.e. megakaryocyte and erythroid progenitor cells (MEP), as well as granulocyte and macrophage progenitor cells (GMP). Ultimately,
these dual progenitors originate unilineage committed progenitors for megakayocytes (MkP), erythrocytes (EP), monocytes (MP), and granulocytes (GP). Some of the best
characterized cytokines regulating the proliferation/differentiation processes are indicated in the ﬁgure. Arrows indicate activating events, whereas perpendicular lines highlight
inhibitory events.
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initial expansion followed by a depletion of LT-HSCs. This transient
increase in HSC number was due to enhanced cell cycle progression,
that, however, ultimately resulted in exhaustion of the HSC
population [84]. Rapamycin reverted the phenotype of PTEN-deﬁcient
HSCs, suggesting that mTORC1 signaling was responsible for this
phenotype [85]. These results have been conﬁrmed by others, who,
however, highlighted that Wnt/β-catenin/GSK3β signaling could be
upstream of mTORC1 activity in the regulation of HSC homeostasis in
mice [86].
Different genetic strategies for activatingmTORC1 signaling have led
to essentially similar results. TSC1 deﬁcient mice also displayed initial
increased HSC proliferation, leading to short-term expansion but long-
term depletion of HSCs [87,88]. TSC1 deletion resulted in higher
mTORC1 activity that promoted HSC proliferation. These proliferating
HSCs displayed dramatically elevated reactive oxygen species (ROS)
levels which were responsible for the depletion, as a ROS-scavenger
(N-acylcysteine) signiﬁcantly rescued the repopulating activity of the
mutant HSCs [87]. Indeed, it is well established that ROS dramatically
limit the lifespan of HSCs [89] and the bone marrow HSC niche is
thought to be a low-oxygenic environment that impairs ROS production
[90]. ROS overproduction that characterizes TSC1−/− HSCs most likely
has a mitochondrial origin, as it has been found that the mitochondrial
mass andmitochondrial DNAwere approximately two-fold increased in
these genetically-modiﬁed HSCs. Moreover, the expression levels of
mitochondrial oxidative genes were also signiﬁcantly upregulated in
TSC1-deﬁcient HSCs, suggesting high levels of mitochondrial oxidative
activity and ROS generation [87].
Also overexpression of Rheb2 caused a transient expansion of
mouse HSCs, but these cells were signiﬁcantly impaired in their abilityto repopulate primary and secondary congenic transplant recipients
[91]. At least another mTORC1 regulator plays a similar role in the
maintenance of HSC properties. Promyelocytic leukemia (PML) gene
deﬁcient mice exhibited short-term increased but long-term de-
creased HSC repopulating activity [92]. HSCs with PML knockout
exhibited mTORC1 hyperactivation and rapamycin rescued the
repopulation defect observed in these mutant mice. In a previous
study, this group had demonstrated that PML sequestered mTOR into
nuclear bodies and inhibited mTORC1 functions under hypoxic
conditions [93]. Therefore, when PML was deleted, signaling down-
stream of mTORC1 was upregulated, leading to HSC exhaustion.
Intriguingly, recent ﬁndings have documented that mTORC1
activity was higher in HSCs from old mice compared to those from
young mice [94]. If mTORC1 was activated in young mice HSCs by
conditional deletion of TSC1, these cells displayed an impaired
capacity to reconstitute the hematopoietic system. In old mice,
rapamycin increased the life span and restored the self-renewal/
hematopoietic activity of HSCs, suggesting that mTORC1 inhibitors
may have the potential to improve hematopoiesis in the elderly, who
frequently displays anemia. Thus, these ﬁndings are in agreement
with the emerging theory that dampeningmTORC1 activity could lead
to widespread protection from an array of age-related disorders [95].
Members of the FOXO family of transcription factors, FOXO1,
FOXO3, and FOXO4 are substrates of Akt, that inactivates their
transcriptional activity by increasing FOXO 14-3-3 protein dependent
export into the cytoplasm [96]. It has been reported that FOXO factors
are critical for the long-term maintenance of HSCs. Mice in which
FOXO1, FOXO3, and FOXO4 were conditionally and concomitantly
deleted in the adult hematopoietic system, displayed a marked
reduction of HSC number and function in response to physiologic
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increase in ROS levels in FOXO-deﬁcient HSC comparedwithwild-type
HSC. This correlatedwith changes in expression of several geneswhich
regulate ROS production, including GADD45 (Growth Arrest and DNA
Damage45), catalase, and superoxide dismutase (Sod), Sod1 and Sod3.
Furthermore, aged FOXO3a knockout animals also displayed a
reduction of the HSC pool and an impaired repopulating capacity in
serial transplantation assays, accompanied by elevated p38 mitogen-
activated protein kinase activity and ROS levels [98]. Increased exit
fromquiescence and enhanced apoptosis, two of the features observed
in FOXO-deﬁcientmutants, could act together to decrease the pool size
of HSCs available for self-renewal [99]. Intriguingly, these ﬁndings
were in agreement with an earlier observation that documented
the importance of PI3K/Akt/FOXO3 signaling for the survival of Lin−
mouse hematopoietic progenitor cells challenged with SCF [100].
These observations beg the question of which factors could regulate
HSC quiescence and proliferation. It has been proposed that CXCL12
(for CXC chemokine ligand 12, previously referred to as stroma-
derived factor-1α or SDF-1α) and transforming growth factor β
(TGFβ) play key roles in the regulation of HSC cell cycle status [101].
CXCL12 is abundantly secreted by the osteoblasts which line the HSC
niche, while HSCs express high levels of the CXCL12 receptor, CXCR4
[67]. CXCL12 acted as a survival and proliferation factor for human
CD34+ cells by upregulating proteins which accelerated cell cycle
progression, while TGFβ blocked progression through the G1 phase of
the cell cycle. Interestingly, CXCL12 treatment of human CD34+ cells
isolated from the peripheral blood, resulted in activation of PI3K/Akt/
mTORC1 signaling, while TGFβ opposed pathway upregulation [101].
In this humanmodel, FOXO3awas identiﬁed as an importantmediator
of the opposing effects of the two cytokines on HSCs, as CXCL12
increased FOXO3a phosphorylation, whereas TGFβ downregulated it.
Indeed, in CD34+ cells overexpressing a non-phosphorylatable formof
FOXO3a, CXCL12 did not promote cell cycle progression [101]. Another
clue to the involvement of PI3K/Akt/mTORC1 signaling in HSC
functions comes from the observation that SHIP1 deletion, that leads
to pathway upregulation, initially resulted in higher proliferation of
LT-HSCs, but reduced their long-term repopulation capacity [102].
However, SHIP1 is also expressed in cells comprising the HSC niche, so
that SHIP1 deletion also profoundly altered the functions of these cells,
including their chemokine production and their ability to control HSC
proliferation and retention. Therefore, it has been hypothesized that
while PTEN is probably the dominant inositol phosphatase that
restrains PI3K signaling in HSCs, SHIP1 could be the dominant inositol
phosphatase in the cells of the bonemarrownichewhich support HSCs
[103].
5.2. Lineage commitment
Lineage commitment is the process by which a multipotent stem
or progenitor cell becomes increasingly restricted in its lineage fate
options, to eventually (or directly) develop into a fully committed
progenitor of a single cell lineage [57]. Transplantation of sublethally
irradiated β2microglobulin−/−NonObese Diabetic/Severe Combined
Immunodeﬁcient (NOD/SCID) mice with CD34+ cells overexpressing
constitutively active Akt, resulted in enhanced monocyte and
neutrophil development, whereas a dominant negative Akt construct
induced eosinophil development in vivo [104]. Interestingly, it has
been reported that either pharmacological inhibition of PI3K/Akt
signaling or ectopic expression of a dominant negative Akt resulted in
upregulated phosphorylation of CCAATT/enhancer binding protein α
(C/EPBα) in neutrophil progenitors, whereas GSK3β inhibition
lowered C/EPBα phosphorylation levels. Furthermore, the expression
of constitutively active Akt caused a marked decrease in the
expression levels of Jun B, a C/EPBα transcriptional target [104].
This would imply that Akt could control C/EPB α phosphorylation
through GSK3β, thus inﬂuencing lineage choice decisions duringmyelopoiesis. It should be emphasized here that C/EPBα is one of the
key transcription factors which regulate lineage choices during
myelopoiesis [105] and its phosphorylation on Ser21 can inhibit
granulocytic differentiation [106]. The importance of PI3K/Akt/
GSK3β and Wnt/GSK3β signaling pathway cross-talks during myelo-
poiesis has been emphasized by others [107].
5.3. Erythropoiesis
Erythrocyte production is tightly regulated by the cytokines EPO
and SCF, which sustain the proliferation, survival, and differentiation
of erythroid progenitors [108–111]. EPO and SCF activate common
signaling pathwayswhich include JAK/STAT5, Ras/Raf/MEK/ERK, and
PI3K/Akt/mTOR [112].When comparedwith EPO, SCF is amuchmore
potent Akt activator [113]. However, SCF could not induce cell survival
in the absence of EPO [114]. Instead, SCF signaling delayed differen-
tiation, thatwas increased by the PI3K inhibitor, LY294002 [113]. Upon
EPO binding to its receptor (EPOR), the EPOR is tyrosine phosphor-
ylated and recruits Src homology-2 (SH2) domain-containing pro-
teins, thereby activating different signaling cascades (see above)
[115,116]. Alternatively, EPO could lead to PI3K/Akt/mTOR activation
through phosphorylation of the growth factor-bound protein (Grb)-
associated binder (Gab), or through phosphorylation of the IRS2
adaptor protein [117]. Gab could then impinge upon Ras signaling,
which is known to be critical for EPO effects on erythropoiesis [118].
The Akt substrate FOXO3a played a critical role in these EPO- and
SCF-evoked phenomena [119], as its inactivation by Akt resulted in
decreased expression of pro-apoptotic genes [120] and of the cyclin-
dependent kinase inhibitor, p27Kip1 [117]. Furthermore, Akt directly
phosphorylated and activated the transcription factor GATA-1 (Globin
transcription factor-1), a key regulator of erythroid differentiation
[121–123]. The involvement of mTORC1 in EPO signaling was
supported by the increased levels of phosphorylated p70S6K observed
in response to EPO challenging [117]. However, the consequences of
upregulated mTORC1 activity on erythropoiesis are unclear, but could
be related to cell cycle progression. In this context it is important to
emphasize how gene expression proﬁling studies have highlighted
several genes which are under the control of the PI3K/Akt pathway in
human early erythroid progenitors (CD34+CD71+CD45RA−GPA−),
incubated with EPO. The upregulated genes played an important role
during erythroid proliferation/differentiation and included: cyclin D3,
E and A, as well as c-Kit and CDH1 (E-cadherin) [124]. In anothermore
recent study, gene expression proﬁles downstream of mTORC1 were
investigated at the polysomal level, using immortalized erythroblasts
co-stimulated with EPO plus SCF. Nine genes were identiﬁed which
required EPO/SCF stimulation for polysome recruitment and were
downregulated during erythroid differentiation. One of these genes,
Immunoglobulin binding protein 1 (Igbp1), is a regulatory subunit of
PP2A (the α4 subunit of PP2A) that sustains PI3K/Akt/mTORC1
signaling. Constitutive expression of Igbp1 impaired erythroid
differentiation, maintained high levels of 4E-BP1 and p70S6K
phosphorylation, and enhanced polysome recruitment of multiple
eIF4E-sensitive mRNAs. Therefore, it was inferred that PI3K-depen-
dent polysome recruitment of Igbp1 acted as a positive feedback
mechanism on translation initiation, underscoring the important
regulatory role of selective mRNA recruitment to polysomes for ﬁnely
tuning the balance between proliferation and maturation of erythro-
blasts [125].
5.4. Megakaryocytopoiesis
Megakaryocytedifferentiation is characterizedbyendomitosis in the
absence of nuclear and cellular division, thereby increasing DNA and
cytoplasmic content. This leads to the generation of large polyploid cells
with a dramatically increased cytoplasmic volume, the function of
which is to produce and shed platelets [126]. During this process, a
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volved. TPO is the most thoroughly investigated regulator of megakar-
yocyte growth and differentiation. Nevertheless, in addition to TPO,
other cytokines have non-negligible effects on megakaryocytopoiesis,
including CXCL12 [127] and bone morphogenetic protein 4 (BMP4), a
member of the TGFβ family [128].
TPO binds its cognate receptor, the cellular protooncogene c-Mpl,
i.e. the homolog of the murine myeloproliferative leukemia virus
oncogene, v-Mpl [129]. Once activated by TPO engagement, c-MPL
stimulates a series of signal transductions cascades, including PI3K/
AKT/mTOR. [130–132]. Blocking this pathway resulted in inhibition of
TPO-dependent megakaryocyte survival. Nevertheless, PI3K/AKT/
mTOR signaling was necessary but not sufﬁcient for TPO-induced cell
cycle progression in primary megakaryocyte progenitors [133],
implying that other pathways play important roles in the regulation
of cell cycle.
Identiﬁed Akt substrates inmegakaryocytes include FOXO3a [134],
p27Kip1 [135], and GSK3β [136]. One of the fundamental biological
activities of TPO is the prevention of megakaryocyte apoptosis. Akt
activation mediated by TPO, was instrumental for blunting caspase-3-
mediated cleavage of anti-apoptotic Bcl-XL protein. This could be one
of themechanisms bywhich PI3K/Akt signaling counteracts apoptosis
during megakaryocytopoiesis [137]. mTORC1 and its downstream
substrates, p70S6K and 4E-BP1, are critically involved in TPO-induced
proliferation of megakaryocyte progenitors [138], as well as in the late
stages of megakaryocyte differentiation [139]. A recent investigation
has tried to unravel the functions of both mTORC1 and mTORC2 in
MO7e megakaryoblastic cells. By exploiting lentiviral constructs
encoding short hairpin RNA sequences to either Raptor or Rictor, it
was documented that mTORC1 regulated cell growth and size by
inhibiting autophagy, whereas mTORC2 was involved in cell cycle
progression and nuclear ploidity [126]. Nevertheless, it remains to be
established if these ﬁndings would apply also to primary megakar-
yocyte progenitors. Indeed, a previous study had highlighted that in
CD34+ cells, puriﬁed from human peripheral blood and treated with
TPO, rapamycin (that should mainly target mTORC1) strongly
inhibited cell polyploidization [140].
5.5. Granulocytopoiesis/monocytopoiesis
Granulocyte/macrophage-colony stimulating factor (GM-CSF)
[141], granulocyte-colony stimulating factor (G-CSF), and macro-
phage-colony stimulating factor (M-CSF) are key factors for granulo-
cytopoiesis/monocytopoiesis, and there is evidence for an
involvement of PI3K/Akt signaling in these phenomena [141,142].
However, a very recent report has documented that mTORC1
signaling is not essential for myeloid progenitor differentiation [143].
6. PI3K/Akt/mTOR signaling and leukemogenesis
It is generally thought that leukemogenesis involves a series of
alterations, which ultimately transform a normal HSC or a committed
hematopoietic progenitor, into a leukemic stem cell (LSC) capable of
propagating the malignant clone [144]. Over the last 15 years,
remarkable progress has been made in the elucidation of the
molecular pathogenesis of leukemias. This is especially true of acute
myelogenous leukemia (AML) [145,146]. A ‘two hits’ model has
suggested that AML development requires multiple genetic/epige-
netic changes which deregulate different cell programs. Transcription
factor fusion proteins such as AML1/ETO (Acute Myeloid Leukemia1/
Eight Twenty One), PML-RARα (Retinoic Acid Receptor α), CBFβ/
MYH11 (Core Binding Factor β/MYosin Heavy chain locus 11) orMLL/
AF9 (Mixed-Lineage Leukemia/Acute lymphoblastic leukemia 1 Fused
gene from chromosome 9) block myeloid cell differentiation by
repressing target genes, thus providing one necessary event for
leukemogenesis [146]. Disordered cell growth and upregulation of cellsurvival genes is a proposed necessary second event. Mutations in
growth regulatory genes such as FLT3 (Fms-Like Tyrosine kinase 3),
Ras, and c-Kit are common in AML patients, resulting in activation of
multiple signal trasduction pathways which include PI3K/Akt/
mTORC1 [147–149]. There is evidence of great interdependence
between the two classes of molecular events. Indeed, changes in the
transcriptional control in hematopoietic cells could modify the arrays
of signal transduction effectors available for growth factor receptors,
whereas activatingmutations in signal transduction molecules induce
alterations in the activity and expression of several transcription
factors which are essential for normal myeloid differentiation [150].
LSCs share some properties with HSCs, as they are for the most part
quiescent and capable of self-renewing. The quiescence of LSCs could
explain, at least in part, the difﬁculties in eradicating this cell population
by conventional polychemotherapy and the relapseswhich characterize
AML [151].
There are somepaperswhichhavedemonstrated that dysregulated
PI3K/Akt signaling is leukemogenic in mice. For example, hematopoi-
etic cells expressing mutated (active) p110α PI3K forms generated an
acute leukemia-like disease characterized by anemia, neoplastic
inﬁltration of hematopoietic organs, and 90% mortality within
5 weeks, when injected in a syngenic mouse model [152]. A rare,
oncogenetic, activatingmutation (E17K) in the PHdomain of Akt1 that
has been detected in some types of solid cancers (breast, colon, ovary),
was leukemogenic in an in vivo murine model [153]. Intriguingly, this
mutation has been identiﬁed also in pediatric patients with T-cell
acute lymphoblastic leukemia (T-ALL) [154].
Some recent manuscripts have focused on the effects of PI3K/Akt/
mTORC1 signaling activation in HSCs in relationship with the
development of malignant hematological disorders, including leuke-
mias. HSCs without functional PTEN, started to move out of the bone
marrow, colonizing distant organs, and originating ﬁrst a myeloprolif-
erative disorder (MPD) and then an acutemyeloid/lymphoid leukemic-
like disease [84,85]. Rapamycin prevented the development of
leukemia, implying an important role for mTORC1 in leukemogenesis.
A myristoylated allele of Akt1 (myr-Akt1) was introduced into
murine HSCs via retroviral transduction. HSCs in the myr-Akt1 mice
displayed transient expansion and increased cycling, which, however,
were associated with impaired engraftment and subsequent depletion
of the HSC pool [155]. Expression of myr-Akt1 was sufﬁcient to induce
by 6–8 weeks anMPD and a T-cell lymphomawith high frequency (90%
and 65%, respectively), and an AML with a lower penetrance (10%,
without any evidence of preexisting MPD). The importance of mTORC1
signaling in T-cell lymphoma (but not MPD or AML) pathogenesis was
suggested by the signiﬁcantly increased survival observed when myr-
Akt1 mice were treated with rapamycin. Interestingly, in this mice
model no ROS elevation was detected, suggesting that oxidative stress
may not be the only important mechanism for HSC depletion.
Another mTORC1 regulator potentially involved in leukemogen-
esis is TSC1, as TSC1 knockout mice developed an MPD [88]. However,
in another mouse model where TSC1 was deleted, no MPD was
observed. Instead, the authors reported a reduction of myeloid
development [87]. These conﬂicting results have been related to
different deletor strains used in these two studies [76]. However, it
may also be that there are TSC1/mTORC1 independent mechanisms
mediating PI3K/PTEN/Akt signaling functions in HSCs that could be
involved in leukemogenesis. In any case, it is very important to
emphasize here that mTORC1 upregulation exerted a potent pro-
survival effect in human LSCs transplanted in NOD/SCID mice [156].
These ﬁndings indicated that therapeutical targeting of mTORC1 has
the potential for eradicating AML.
In contrast, no AMLwas observed in the conditional FOXO deletion
model [97], despite strong similarities in the HSC phenotype with the
myr-Akt1 mice or the conditional PTEN deletion model. Thus, these
ﬁndings would imply that FOXO transcription factors contribute to
maintenance of normal HSC homeostasis, but are not involved in
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stream targets of Akt, such as mTORC1, are required for leukemic
transformation. Nevertheless, recent ﬁndings have documented the
importance of TGF-β/AKt/FOXO3a signaling for the maintenance of
LSCs in a chronic myelogenous leukemia-like disease mouse model
[157]. Therefore, the importance of FOXO transcription factors in the
pathogenesis of leukemias should be further investigated.
Howwe could reconcile the ﬁnding that enhanced HSC proliferation
followed by their exhaustion leads to leukemia in mouse models?
Cancer development requires the combination of several genetic/
epigenetic alterations,which aid cell transformation. The precedingHSC
proliferation phase caused by an oncogenetic alteration (in our case
PI3K/Akt/mTORC1 upregulation)may be the key feature that promotes
leukemogenesis along with other cooperating hits which rescue HSC
exhaustion. Indeed, there are several genetic alterations which lead to
HSC exhaustion in mice models and cause leukemia. These include,
among the others, Runx1, PU.1, PML, and Rb deletions (see [158] for a
comprehensive and updated review on this topic). This model of
various hits causing leukemia is supported by an investigation that has
documented that PTEN deletion in mouse HSC led to an MPD, followed
by T-ALL. In this model, LSCs showed increased levels of unpho-
sphorylated β-catenin. Conditional ablation of one allele of the β-
catenin gene substantially decreased the incidence and delayed the
occurrence of T-ALL caused by PTEN loss, suggesting that activation of
the β-catenin pathwaymay contribute to the formation or expansion of
the LSC population [159]. Moreover, a recurring chromosomal translo-
cation, T(14;15), resulted in aberrant overexpression of the c-myc
oncogene in T-ALL LSCs, recapitulating a subset of human T-ALL.
Therefore, this intriguing study clearly indicated thatmultiple genetic or
molecular alterations could contribute cooperatively to HSC malignant
transformation and T-ALL development.
There are, however, mouse models which display HSC exhaustion
(for example, knockouts of CDC42, CXCR4 and SHIP1) but have not
been associated with leukemia [158]. Thus, HSC proliferation/
depletion could not invariably precede malignant transformation.
This may depend on how long the aberrant HSCs would persist in the
body, so that additional hits could rescue them before complete HSC
exhaustion takes place. Therefore, the time window for HSC
exhaustion might dictate the incidence of individual hematological
neoplasias in humans [158].
7. Conclusions and future perspectives
Over the last decade, extensive studies carried out in many
laboratories have considerably increased our understanding of the
molecularmechanismswhich are essential for normalmyelopoiesis in
the adult.Fig. 3. Akt is activated in leukemic, but not in healthy, bone marrowmononuclear cells (BMM
were cytocentrifuged, ﬁxed, and permeabilized. They were then stained with antibodies to th
FITC-conjugated antibody, whereas Ser473 p-Akt was labeled with a rhodamine-conjugated
CD33 and Ser473 p-Akt (arrow), while in leukemic BMMCs a strong co-localization (yellow
×600. Scale bar: 15 μM.The ﬁndings reviewed in this article strongly suggest that a
correct regulation of PI3K/Akt/mTORC1 signaling is required for the
ﬁne tuning of multiple processes involved in blood cell production, as
well as in the control of HSC functions. Indeed, a very recent report
has highlighted how both Akt1 and Akt2, by regulating the
intracellular levels of ROS, are necessary for the maintenance of
mouse LT-HSCs [160]. There also is increasing evidence that an
aberrant regulation of the PI3K/Akt/mTORC1 network could con-
tribute to leukemogenesis.
Pharmacological inhibitors of this network are being tested in
many clinical trials for the treatment of cancer patients. Some
inhibitors (rapalogues) have already been approved for clinical use
in some types of neoplasia, including advanced renal cell carcinoma
[161]. Chronic inhibition of PI3K/Akt/mTORC1 signaling may lead to
issues of hematological insufﬁciency in the long term, as suggested,
for example, by the thrombocytopenia that is sometimes (but not
always) detected in patients treated with mTORC1 inhibitors [162].
However, many of the studies regarding PI3K/Akt/mTORC1
signaling and hematopoiesis were performed using in vitro models
and may not necessarily reﬂect the situation in vivo. Although it
seems that the PI3K/Akt/mTORC1 network is important for the
generation of erythrocytes, granulocytes/monocytes, and platelets,
several lines of evidence suggest that pathway inhibitors are much
less toxic to normal myelopoiesis than they are to leukemic cells
[163]. This observation could be explained by putting forward the so
called “oncogenic addiction” hypothesis, where only neoplastic cells
are highly reliant on signaling pathwayswhich have been upregulated
during disease progression enabling their survival [164]. Moreover,
multiple signaling pathways are activated by cytokines. These path-
ways are often redundant and display extensive cross-talks. Thus, it
might be that during normal myelopoiesis other signaling cascades
could substitute for PI3K/Akt activation, such as the MAPK (MAP
kinase) signaling pathways [165].
In this context, it is intriguing that bonemarrowmononuclear cells
from healthy donors did not display PI3K/Akt/mTORC1 pathway
activation, whereas signaling upregulation was easily detected in the
same fraction prepared from patients with neoplastic hematological
disorders, including AML (see Fig. 3 and Refs. [166–168]). It could be
that during normal myelopoiesis activation of this signaling pathway
is a short-lived andmore discrete phenomenon, whereas in leukemias
the phenomenon is long-lasting and widespread.
Remarkably, it is now beginning to emerge that aberrantly activated
PI3K/Akt/mTORC1 signaling is also detectable in cancer stem cells from
different kinds of neoplasia [41,169,170] and that cancer stem cells
displayed preferential sensitivity to pathway inhibitionwhen compared
to healthy stem cells [171,172]. This seems to be true also of HSCs and
LCSs, at least in mice [85].Cs). BMMCs were isolated from a healthy donor (A) and from an AML patient (B). Cells
e myeloid differentiation antigen, CD33, and to Ser473 p-Akt. CD33 was revealed by an
secondary antibody. Note how only two of healthy BMMCs displayed positivity for both
or orange) of the two signals was evident in many of the cells. Original magniﬁcation,
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differences in signaling pathways between neoplastic stem cells and
healthy stem cells could be identiﬁed.
Therefore, further identiﬁcation of speciﬁc PI3K/Akt/mTOR sub-
strates and of their roles in the quiescence, proliferation, survival, and
differentiation of HSCs and LSCs could provide innovative pharmaco-
logical treatments for patients with malignant hematological
disorders.
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